ClinicalTrials.gg
CompletedNCT01129856Updated Apr 27, 2011

Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

A Phase 3 interventional study of Dexamethasone phosphate ophthalmic solution and Sodium citrate buffer solution in Dry Eye, sponsored by Eyegate Pharmaceuticals, Inc.. Completed at 5 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-04-27.

Sponsored by Eyegate Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
111th of 473
198 · median 60
Started
2010
with 22 others
Phase 3
77 of 544
1 open now
Registered
95th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 111th largest by enrollment of the 473 interventional ones that give a count, is one of 23 that started in 2010, is one of 77 in phase 3, and was the 95th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) using the EyeGate® II Iontophoresis system in patients with dry eye.

Read the detailed description

Dry eye is the most prevalent form of ocular discomfort and irritation. Estimates range from 20 million people in the United States being affected with mild to moderate dry eye, to as many as one out of every five Americans.

EyeGate completed a single-center, randomized, double-masked, placebo-controlled Phase 2 efficacy study in 105 subjects with mild to moderate dry eye disease, utilizing the Controlled Adverse Environment (CAE), a clinical model which allows for standardized measurement of dry eye signs and symptoms in the investigation of therapeutic agents. In this Phase 2 study, the improvements documented in dry eye signs and symptoms relative to the placebo group indicated that the ocular iontophoresis treatments with EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis) had both a rapid onset of action and a long-term effectiveness.

The Phase 3 study is intended to confirm and extend the results from the Phase 2 study, utilizing the CAE model. The study is designed to assess the safety and efficacy of EGP-437 at two different dose levels: Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA and Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA compared to Ocular Iontophoresis with placebo (sodium citrate buffer solution) for the treatment of the signs and symptoms of dry eye.

03

Conditions studied

  • Dry Eye

Keywords

  • Dry eye
  • Keratoconjunctivitis sicca
  • Iontophoresis
  • Ophthalmic drug delivery
  • EGP-437
  • Dexamethasone phosphate
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a reported history of dry eye in each eye
  • Be at least 12 years of age
  • Demonstrate a response when exposed to the Controlled Adverse Environment model at Visits 1 and 2

Exclusion criteria

Exclusion Criteria:

  • Have to the use of the test articles
  • Have known allergy or sensitivity to the study medications or their components
  • Have any ocular infections, active ocular inflammation, or preauricular lymphadenopathy
  • Be current contact lens wearers or wear contacts during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
198 participants (actual)

Study arms

  • Active comparator
    Ocular Iontophoresis EGP-437, Low Dose

    Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA

    Drug: Dexamethasone phosphate ophthalmic solution

  • Active comparator
    Ocular Iontophoresis EGP-437, High Dose

    Ocular Iontophoresis with EGP-437 6.5 mA-min at 2.5 mA

    Drug: Dexamethasone phosphate ophthalmic solution

  • Placebo comparator
    Ocular Iontophoresis Placebo

    Ocular Iontophoresis with Placebo 6.5 mA-min at 2.5 mA

    Drug: Sodium citrate buffer solution

Interventions

  • Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)

  • DrugSodium citrate buffer solution

    Sodium citrate buffer solution 100 mM

06

What researchers measure

Primary outcomes

  1. Sign: Differences in corneal fluorescein staining (inferior region, Ora Scale) Visit 1 Pre-CAE to Visit 6 compared to placebo; Symptom: Ocular discomfort at Visit 5 as compared to placebo

    Time frame: Up to 10 weeks

Secondary outcomes

  1. Sign: Corneal fluorescein staining (each region, Ora Scale); Symptom: Ocular discomfort pre- and post-CAE (Ora Scale)

    Time frame: Up to 10 weeks

07

Study locations

5 sites
  • The Eye Care Group
    Waterbury, Connecticut 06708, United States
  • Central Maine Eye Care
    Lewiston, Maine 04240, United States
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
  • Total Eye Care
    Memphis, Tennessee 38119, United States
  • Virginia Eye Consultants
    Norfolk, Virginia 23502, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jan 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2010
First posted
May 25, 2010
Start
Jun 2010
Primary completionActual
Jan 2011
CompletionActual
Apr 2011
Last update
Apr 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01129856
Lead sponsor
Eyegate Pharmaceuticals, Inc.
First posted
May 25, 2010
Start date
Jun 2010
Primary completion
Jan 2011
Completion
Apr 2011
Last update
Apr 27, 2011

Study contacts

Gail L Torkildsen, MD
principal investigator · Andover Eye Associates

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion